News

The Pilot Longitudinal Study in Alzheimer’s Disease of Central Markers of Microglial Activation (PADMMA) combines brain imaging with key biomarkers to identify the role of inflammation in neurodegenerative

As part of this plan, the Company has signed two collaborations, one with the Croix-Rousse Hospital, Hepato-Oncology Team and the Centre de Recherche en Cancérologie, Inserm U1052, in

The IND will enable Janssen, Aduro’s license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741

AZD2811, a novel, selective inhibitor of Aurora B kinase that has been shown to be active in both solid and hematological tumors in preclinical models, is the second

A CRL is a communication from the FDA that informs companies that an application cannot be approved in its present form. In the letter, the FDA requested additional

Crown Bioscience president Jean-Pierre Wery said: "Crown’s suite of in vitro and in vivo immuno-oncology assays employing translational experimental models help inform and accelerate the development of cancer

A total of 117 patients were enrolled at over 20 sites in the US and Canada for the company’s PUNCH CD 2 multi-center, randomized, double-blind, placebo-controlled trial to

Novartis unit Sandoz is seeking approval for the similar indication as the reference product. The company said the totality of evidence in its submission, including three clinical trails,

Avelumab, also known as MSB0010718C, inhibits PD-L1 interactions to potentially allow the activation of T-cells and the adaptive immune system. It is believed to engage the innate immune